NCT00725764View on ClinicalTrials.gov

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 27, 2007

Primary Completion Date

May 2, 2009

Study Completion Date

May 2, 2009

Conditions
Neoplasms, Head and Neck
Interventions
DRUG

GSK1363089 (foretinib)

Multitargeted tyrosine kinase inhibitor

Trial Locations (11)

28506

GSK Investigational Site, Morgantown

29403

GSK Investigational Site, Charleston

30309

GSK Investigational Site, Atlanta

37203

GSK Investigational Site, Nashville

46254

GSK Investigational Site, Indianapolis

60637

GSK Investigational Site, Chicago

63110

GSK Investigational Site, St Louis

77030

GSK Investigational Site, Houston

78229

GSK Investigational Site, San Antonio

55407-3799

GSK Investigational Site, Minneapolis

03756

GSK Investigational Site, Lebanon

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00725764 - Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck | Biotech Hunter | Biotech Hunter